Table IV.

T-cell therapy studies for EBV reactivation and post-transplant lymphproliferative disorder occurring after HSCT.

Reference	n	HSCT type	Strategy	End points	Results
Gustafsson, 2000 (43)	9	MRD, MUD, MMUD	Pre-emptive therapy	Antiviral effect	➢2–4 log decrease in EBV viral load in 4 patients ➢EBV stabilization in 1 patient ➢1 case of progressive PTLD
Leen, 2006 (11) and Hanley 2013 (15)	34	MRD, MUD, haplo	Prophylaxis Pre-emptive therapy PTLD treatment	Safety Efficacy CTL expansion	➢No GvHD ➢10/10 patients with high EBV load cleared the virus ➢Up to 5-fold increase in EBV-specific T cells
Comoli, 2007 (44)	4	Haplo	Prophylaxis	Safety Efficacy	➢No adverse events ➢EBV DNA cleared in all patients
Leen, 2009 (46)	12	Haplo, MUD	Prophylaxis	Safety Efficacy	➢No de novo GvHD ➢9 patients remained EBV-free ➢3 patients had increased viremia, cleared spontaneously
Heslop, 2010 (45)	114	MRD, MUD, haplo	Prophylaxis (101 patients) PTLD treatment (13 patients)	Safety Efficacy	➢No de novo GvHD ➢8 patients had GvHD recurrence after CTL ➢0% PTLD incidence versus 11% in patients treated in same protocol without CTL ➢85% of patients affected by PTLD achieved CR with CTL
Hanley, 2012 (51)	7	Cord blood	Prophylaxis treatment	Safety Efficacy CTL expansion	➢No GvHD ➢7/7 patients engrafted using only 80% of the cord blood unit ➢CTL clones detected >1 y after infusion ➢6 patients remained EBV-free, 1 patient had EBV but cleared spontaneously with detectable EBV-specific T cells